Page 41 - Read Online

Benhammou et al. Hepatoma Res 2020;6:35 I http://dx.doi.org/10.20517/2394-5079.2020.16 Page 13 of 15

cirrhotic individuals. Sci Rep 2017;7:4492.
51. Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, et al. Rare pathogenic variants predispose to hepatocellular carcinoma in
nonalcoholic fatty liver disease. Sci Rep 2019;9:3682.
52. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States.
Arch Intern Med 2007;167:1983-9.
53. Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, et al. Racial and ethnic differences in presentation and outcomes of
hepatocellular carcinoma. Clin Gastroenterol Hepatol 2019;17:551-9.e1.
54. Garske KM, Pan DZ, Miao Z, Bhagat YV, Comenho C, et al. Reverse gene-environment interaction approach to identify variants
influencing body-mass index in humans. Nat Metab 2019;1:630-42.
55. Benhammou JN, Ko A, Alvarez M, Kaikkonen MU, Rankin C, et al. Novel lipid long intervening noncoding RNA, oligodendrocyte
maturation-associated long intergenic noncoding RNA, regulates the liver steatosis gene stearoyl-coenzyme a desaturase as an enhancer
RNA. Hepatol Commun 2019;3:1356-72.
56. Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, et al. DNA methylation-based prognosis and epidrivers in hepatocellular
carcinoma. Hepatology 2015;61:1945-56.
57. Fei Q, Shang K, Zhang J, Chuai S, Kong D, et al. Histone methyltransferase SETDB1 regulates liver cancer cell growth through
methylation of p53. Nat Commun 2015;6:8651.
58. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of
hepatocellular carcinoma. Nat Mater 2017;16:1155-61.
59. Ng CKY, Di Costanzo GG, Terracciano LM, Piscuoglio S. Circulating cell-free DNA in hepatocellular carcinoma: current insights and
outlook. Front Med (Lausanne) 2018;5:78.
60. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology
2004;126:460-8.
61. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated
with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012;107:46-52.
62. Chen HF, Chen P, Li CY. Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex
stratifications. Hepatology 2010;52:155-63.
63. Simon TG, King LY, Chong DQ, Nguyen LH, Ma Y, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma:
results from two prospective cohort studies. Hepatology 2018;67:1797-806.
64. Cancer Prevention Study II. The American Cancer Society Prospective Study. Stat Bull Metrop Insur Co 1992;73:21-9.
65. Karagozian R, Derdak Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 2014;63:607-17.
66. Ioannou GN, Weiss NS, Boyko EJ, Kowdley KV, Kahn SE, et al. Is central obesity associated with cirrhosis-related death or
hospitalization? A population-based, cohort study. Clin Gastroenterol Hepatol 2005;3:67-74.
67. Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, et al. Abdominal obesity, weight gain during adulthood and risk of liver
and biliary tract cancer in a European cohort. Int J Cancer 2013;132:645-57.
68. Pang Q, Zhang JY, Song SD, Qu K, Xu XS, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass
index. World J Gastroenterol 2015;21:1650-62.
69. Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet
2004;363:157-63.
70. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, et al. Metabolic syndrome increases the risk of primary liver cancer in the
United States: a study in the SEER-Medicare database. Hepatology 2011;54:463-71.
71. Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, et al. Metabolic risk factors and primary liver cancer in a prospective study
of 578,700 adults. Int J Cancer 2012;131:193-200.
72. Chiang CH, Lee LT, Hung SH, Lin WY, Hung HF, et al. Opposite association between diabetes, dyslipidemia, and hepatocellular
carcinoma mortality in the middle-aged and elderly. Hepatology 2014;59:2207-15.
73. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690-5.
74. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. The diagnosis and management of non-alcoholic fatty liver disease:
practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American
College of Gastroenterology. Gastroenterology 2012;142:1592-609.
75. Bays H, Cohen DE, Chalasani N, Harrison SA, The national lipid association’s Statin safety task F. An assessment by the Statin Liver
Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S47-57.
76. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology
2009;50:1827-38.
77. Chiappini F, Coilly A, Kadar H, Gual P, Tran A, et al. Metabolism dysregulation induces a specific lipid signature of nonalcoholic
steatohepatitis in patients. Sci Rep 2017;7:46658.
78. Walle P, Takkunen M, Männistö V, Vaittinen M, Lankinen M, et al. Fatty acid metabolism is altered in non-alcoholic steatohepatitis
independent of obesity. Metabolism 2016;65:655-66.
79. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat
content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2085-91.e1.
80. Ajmera VH, Cachay E, Ramers C, Vodkin I, Bassirian S, et al. MRI assessment of treatment response in HIV-associated NAFLD: a
randomized trial of a stearoyl-coenzyme-A-desaturase-1 inhibitor (ARRIVE Trial). Hepatology 2019;70:1531-45.